Biopharma · global
Sac-TMT and Keytruda Outperform Standard Chemotherapy-Containing Combination, Signaling a Potential Chemotherapy Alternative in First-Line Lung Cancer Treatment
This global phase 3 trial pushes an ADC plus immunotherapy directly into the first-line lung cancer arena; although the win still lacks the support of full data, it has already given the treatment landscape after Keytruda a clearer direction.
For patients with advanced non-small cell lung cancer, every advance in first-line treatment is not just an adjustment in drug sequencing, but a question of whether disease control can be extended while reducing the burden of traditional chemotherapy. Sac-TMT, a TROP2 antibody-drug conjugate jointly developed by Kelun-Biotech and Merck, was used this time in combination with Keytruda and beat the standard first-line regimen of Keytruda plus chemotherapy in a global phase 3 trial, making “ADC plus immunotherapy” no longer merely an idea for later-line treatment or specific patient groups.
According to reports from BioPharma APAC and Investor's Business Daily, the study enrolled patients with previously untreated non-small cell lung cancer, with the control arm using Keytruda plus chemotherapy, a common approach in Western markets. The trial results showed that Sac-TMT plus Keytruda was superior to the standard combination in progression-free survival, and overall survival also showed a positive trend. However, the information disclosed so far remains relatively broad, and full hazard ratios, patient stratification, follow-up duration, and safety details have not yet been seen.
Sac-TMT is an antibody-drug conjugate designed to use an antibody to recognize TROP2 on the surface of tumor cells and then deliver a cytotoxic drug near cancer cells. Drugs of this type are often described as more precise chemotherapy carriers, but their clinical significance is not that they have no toxicity at all; rather, it is whether they can push the balance between efficacy and side effects beyond that of traditional chemotherapy. When combined with the PD-1 immune checkpoint inhibitor Keytruda, the scientific hypothesis is that tumor killing and immune response can be enhanced at the same time.
This result drew attention from investment institutions because the control arm was not a weaker monotherapy, but an already widely used first-line backbone such as Keytruda plus platinum-based chemotherapy. Investor's Business Daily cited views from RBC and Leerink analysts, who said the result validates the direction of combining ADCs with immuno-oncology therapies and increases the possibility that Sac-TMT could eventually replace part of the role of platinum-based chemotherapy. This interpretation contains an element of market expectation, and clinically it still remains to be seen whether the full data can support a broad shift.
Background Context
Non-small cell lung cancer accounts for the majority of lung cancer cases. In recent years, first-line treatment has shifted from chemotherapy alone toward the combined use of immunotherapy, chemotherapy, and targeted therapy according to molecular characteristics. For patients without clear driver gene mutations, or whose PD-L1 expression is insufficient for immunotherapy alone, chemotherapy-containing combinations remain an important option. That is why a regimen that is not centered on traditional chemotherapy but can outperform the existing standard would generate greater clinical and commercial imagination.
Merck also faces its own timing pressure. Keytruda has long been one of the world's most important cancer drugs, but patent and competitive pressures are approaching; if Sac-TMT can become a new combination backbone for Keytruda, it would help extend the life cycle of its oncology treatment landscape. Kelun-Biotech, through this multinational collaboration, is also moving Chinese ADC research and development from regional data onto a stage subject to greater scrutiny from global regulators and the clinical community.
The real dividing line will come with the full results later disclosed at medical meetings or in journals: which PD-L1 expression groups benefit most, whether the regimen is applicable to different squamous and non-squamous subtypes, whether overall survival can mature into a clear advantage, and whether adverse events are lower than, or at least acceptable relative to, the chemotherapy standard. The current signal is already enough to change the direction of discussion, but rewriting first-line treatment practice will still require more transparent data to turn this direction into an assessable balance of risk and benefit.